Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 1 - Genitourinary tumours, non-prostate

LBA103 - ICRA: Efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1

Date

21 Oct 2023

Session

Proffered Paper session 1 - Genitourinary tumours, non-prostate

Topics

Immunotherapy

Tumour Site

Urothelial Cancer

Presenters

Sarah M.H. Einerhand

Citation

Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. 10.1016/S0923-7534(23)04149-2

Authors

S.M.H. Einerhand1, J. van Dorp2, J. de Feijter1, A. Daletzakis3, S. Oosting4, C. Bruijnen5, B.B. Suelmann5, M.S. van der Heijden1

Author affiliations

  • 1 Medical Oncology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 2 Molecular Carcinogenesis Department, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 3 Biometrics, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 4 Medical Oncology Department, UMCG - University Medical Center Groningen, 9700 RB - Groningen/NL
  • 5 Cancer Center, UMC - University Medical Center Utrecht, 3584 CX - Utrecht/NL

Resources

This content is available to ESMO members and event participants.

Abstract LBA103

Background

The prognosis of metastatic urothelial carcinoma (mUC) patients (pts) after platinum-based chemotherapy and anti-PD-(L)1 is poor. Taxanes can provide disease control and may affect the tumor micro-environment. Clinical activity of anti-CTLA4 has been reported previously and may be dose-dependent. We evaluated whether paclitaxel (P) with tremelimumab (T), with or without durvalumab (D), could induce response in therapy-refractory mUC pts.

Methods

ICRA is an open-label, randomized, multicenter phase I/II study in pts with mUC who relapsed after platinum-based chemotherapy and anti-PD-(L)1. In the safety run-in phase (n=15), we tested weekly P (70mg/m2; day 1, 8, and 15 for 6 cycles (C)) plus either T75mg, T225mg or T750mg (C2-8 every 4 weeks), or P combined with D (C2-12 every 4 weeks) plus either T75mg (C2-5 every 4 weeks) or T300mg once (C2). In the expansion phase (n=12 per arm), pts received (A) P (C1-6) plus T750mg (C2-8); (B) P (C1-6) plus T300mg once (C2) plus D1500mg (C2-12); or (C) T750mg (C1-7). Arm A was extended to n=20 based on 2 responses. The primary endpoint was the objective response rate (ORR) according to RECIST1.1, with a target ORR 30% and aim to exclude 10% (Simon’s optimal two-stage design, α=0.12, power=0.85). Safety was assessed according to the CTCAEv5.

Results

The primary endpoint was met with an ORR of 26% (88%CI 14-37%; 5/19 evaluable pts) in arm A. The ORR was 8% in arms B and C. Median OS (95%CI) was 16.0 (4.4-27.5), 13.9 (9.5-18.3), and 6.6 (0.0-14.8) months in arms A, B, and C, respectively (p=0.68). Median PFS was 5.7 (4.0-7.3), 6.5 (3.7-9.4), and 2.8 (0.0-5.7) months in arms A, B, and C, respectively (p=0.27). Toxicities are summarized in the Table. Table: LBA103

Toxicity

R1 (P+T75) R2 (P+T225) R3B (P+T75+D1500) A (P+T750)1 B (P+T300+D)1 C (T750)
n=3 n=3 n=3 n=20 n=12 n=12
Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3
Therapy-related AEs (n, %) 3 (100) 1 (33) 3 (100) 1 (33) 3 (100) 0 (0) 20 (100) 11 (55) 11 (92) 8 (67) 11 (92) 4 (33)
Immune-related AEs (n, %) 0 (0) 0 (0) 0 (0) 0 (0) 2 (67) 0 (0) 16 (80) 6 (30) 9 (75) 3 (25) 11 (92) 4 (33)
Chemo-related AEs (n, %) 3 (100) 1 (33) 3 (100) 1 (33) 3 (100) 0 (0) 19 (95) 6 (30) 11 (92) 8 (67) n.a. n.a.

AEs=adverse events; D=durvalumab; P=paclitaxel; R=run-in arm; T=tremelimumab 1. Run-in arms 3A and 4 were included in arms A and B of the expansion phase, respectively.

Conclusions

In heavily pretreated patients with mUC, P+T750mg showed a manageable safety profile and encouraging antitumor activity, suggesting a potential synergistic effect of taxanes and high-dose anti-CTLA4.

Clinical trial identification

NCT03871036.

Editorial acknowledgement

Legal entity responsible for the study

Netherlands Cancer Institute.

Funding

AstraZeneca.

Disclosure

J. de Feijter: Financial Interests, Institutional, Advisory Board: Merck. S. Oosting: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Genmab; Financial Interests, Institutional, Invited Speaker: Merck; Financial Interests, Institutional, Research Grant, Investigator initiated research: Celldex; Financial Interests, Institutional, Research Grant, Investigator initiated study: Pfizer, Novartis; Financial Interests, Institutional, Research Grant, I am the principle investigator of EORTC 2120 for which EORTC has received funding from Merck.: Merck; Non-Financial Interests, Institutional, Product Samples: Celldex, Pfizer, Novartis; Other, Member of steering and safety monitoring committee, unpaid.: ALX Oncology. B.B. Suelmann: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Pfizer, Ipsen, Eisai, Merck, MSD; Financial Interests, Institutional, Research Grant, Investigator-initiated study: Pfizer; Financial Interests, Institutional, Research Grant: IPSEN, AstraZeneca, Merck. M.S. van der Heijden: Financial Interests, Institutional, Advisory Board: AstraZeneca, BMS, Janssen, MSD, Seagen, Pfizer; Financial Interests, Institutional, Funding, Investigator-initiated trial: BMS, Roche, AstraZeneca, 4SC; Financial Interests, Institutional, Steering Committee Member, Local PI + SSC member: BMS, AstraZeneca, MSD, Seagen; Financial Interests, Institutional, Steering Committee Member, Local PI + study co-PI: Janssen; Financial Interests, Institutional, Local PI: GSK. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.